Beam Therapeutics Inc.
BEAM-302
alpha-1 antitrypsin deficiency (AATD)
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for BEAM-302 in alpha-1 antitrypsin deficiency (AATD) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Beam expects to present detailed and updated BEAM-302 data at a medical congress in 2026.”